Final decision for NeoPath's primary screener soon:
This article was originally published in Clinica
Executive Summary
NeoPath, the first company to receive an FDA panel approval recommendation for primary use of its automated cervical screening device, said it expected to resolve conditions laid down by the panel shortly (see Clinica No 794, p 15). Labelling conditions, which must be resolved before the company's AutoPap system can be approved, were identified in a letter to the company from the FDA. "The FDA states that it is committed to providing the company with a decision letter on its PMA as soon as possible" said the company.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.